Clinical Trial Update: EPO906 Therapy in Patients With Advanced Kidney Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of EPO906 Therapy in patients with advanced kidney cancer has completed, with an update from Novartis on the study status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Cancer
• Renal Cell Carcinoma

Drugs mentioned

• EPO906 Therapy

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Kidney Neoplasms | Phase 2 | Status: COMPLETED